A Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors
NCT #
NCT05768932
Condition(s)
Solid Tumor
Molecular Target(s)
TTK (MPS1) PLK1
Drug Classification(s)
Immunotherapy (Targeted), Small Molecule
Agents(s)
BAL0891
Phase(s)
I/II
Mechanism of Action
BAL0891 is a small-molecule inhibitor of TTK and PLK1 . Inhibition of both kinases may lead to disruption of the spindle assembly checkpoint (SAC) driving the cells through mitosis before the chromosomes are properly aligned leading to premature cell division and tumor cell death.
Purpose
In this study, the sponsor and investigators want to learn:
- How much of the study drug can be given with an acceptable level of side effects alone or in combination with carboplatin or paclitaxel
- The effects of the study drug (good and bad)
- How much of the study drug is absorbed into the blood and how fast it is removed
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRAS
Solid Tumor
Yes
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
CDK2
Solid Tumor
No
JIT-TSC-007
n/a
Molecular Targeted Therapy
TSC1, TSC2
Solid Tumor
No
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.